[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fQmkPwNGh2WnzfgvFk4sVmjCI5mgKeVZ6S5xAZlZkPQ0":8,"$fZ_Wy_FIOzOdwK8Cxncsm4kn9nE2ECrDclwyeBW-9TZI":61,"$f7hhtasLKkCHYfCUUqOB8lfaVk2rmCpIQ89woeWoW0P8":62,"$fuDB144yb7-zwBjDEwwJJJSaJ-2CbnYHoL4Hz6BJK3YA":66},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":60},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"roleType":17,"adept":18,"hospital":19,"department":20,"postsTitle":21,"materialTotal":17,"videoTotal":22,"isConcern":7,"title":23,"coverVertical":24,"coverAcross":25,"directionMarker":26,"description":27,"vid":28,"time":29,"mediaType":30,"views":31,"likes":17,"isThumbsUp":7,"isCollection":7,"collections":17,"createTime":32,"seoTitle":33,"seoKeywords":34,"seoDescription":35,"shelvesTime":36,"menus":37,"menuId":39,"type":26,"quality":57,"commentCount":17,"isComment":30,"deviceType":58,"url":59},7002,863398,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//W6OyePPo6ps051zACW5hlRIUH6DBCgnt.png","刘芬",0,"各种肿瘤的诊治","宁乡市人民医院","肿瘤科","主治医师",13,"3C期直肠癌：XELOX化疗方案如何提升5年生存率？专家揭秘关键数据","https://cdn.yishi-tong.com/console/3/2Y2MVntPpmO9stm3QcRVQiHPmg5EO773.png","https://cdn.yishi-tong.com/console/3/rnwMg_LcBEDS_WecJFCU-3MLLmLSeUOQ.png",2,"\n\n大家好，我是宁乡市人民医院肿瘤科的刘芬医生。今天我们来聊聊直肠癌，特别是3C期直肠癌患者的治疗方案。我们有一位72岁的女性患者，居住在长沙市，因间断性便血入院，经过检查确诊为直肠高-中分化腺癌，并侵犯阴道，临床分期为IIIC期。\n\n在她的治疗中，我们选择了XELOX化疗方案，这是一种结合了奥沙利铂和卡培他滨的化疗方案。XELOX方案的优势在于其良好的疗效和相对较低的副作用。对于3C期直肠癌患者，XELOX方案能够有效地控制肿瘤生长，提高患者的生存率。\n\n根据临床数据，XELOX方案在3C期直肠癌患者中的5年生存率显著高于传统化疗方案。这是因为XELOX方案能够更好地靶向癌细胞，同时减少对正常细胞的损伤，从而降低了化疗引起的不适感。我们的患者在化疗后没有明显的不适，顺利出院，这也反映了XELOX方案的有效性。\n\n当然，XELOX方案并不是适用于所有患者。在选择治疗方案时，我们需要综合考虑患者的年龄、身体状况以及其他合并症。我们的患者有高血压病、颈动脉硬化等多种基础疾病，因此在治疗过程中，我们也密切关注她的整体健康状况。\n\n在出院时，我们给患者提供了详细的医嘱，包括注意饮食和生活起居，定期复查血常规及肝肾功能。如果出现便血等不适症状，需及时就医。这些都是为了确保患者在后续的治疗和恢复过程中能够得到良好的监测和支持。\n\n总之，3C期直肠癌的治疗需要个体化的方案，XELOX化疗方案为患者提供了一个有效的选择。希望通过今天的分享，能够让更多患者了解这一治疗方案的优势，增强对抗癌症的信心。","v0247cg10004d1553u2ljht831lkvp9g",182,1,339,"2025-06-03 14:10:01","3C期直肠癌XELOX化疗方案：专家揭秘5年生存率提升关键数据  ","3C期直肠癌,XELOX化疗方案,5年生存率,直肠癌治疗,奥沙利铂,卡培他滨,化疗效果,肿瘤专家  ","权威专家解析3C期直肠癌采用XELOX化疗方案（奥沙利铂+卡培他滨）的核心疗效数据，揭示其提升患者5年生存率的关键机制及临床研究证据，为患者提供科学治疗参考。","2025-06-14 00:34:00",[38],{"menuId":39,"menuName":40,"parentId":17,"orderNum":41,"path":42,"component":43,"isFrame":44,"isCache":45,"menuType":46,"visible":30,"status":17,"createDept":6,"remark":47,"createTime":48,"children":49,"columnImage":50,"columnLogo":51,"uncheckedLogo":6,"checkedLogo":6,"isHot":17,"isHome":17,"forceLogin":17,"color":6,"seoTitle":52,"seoKeywords":53,"seoDescription":54,"contentNum":6,"promotionalPoster":55,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":56,"routerPath":42,"componentInfo":43},"1986622624134549505","科普视频",3,"video","/video.html","1","0","T","","2025-11-07 10:31:58",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:40/0d7fcb56-3dc4-4dcb-99ca-a5d5c438378e.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:43/958efac7-dd02-4681-b8fd-0dd84b1bbf42.png","健康科普视频大全,了解你的健康生活","健康科普视频, 戒烟视频, 饮食健康视频, 胸痛科普, 用药知识, 职业健康视频, 贫血科普, 眼健康视频","精选健康科普视频,涵盖戒烟、胸痛、饮食、用药与职业健康等多个主题,让你轻松获取科学健康知识,提升生活质量。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:45/fa8fe113-deaa-4454-8105-d629769963dd.png","Video","癌症肿瘤,重大疾病",4,"https://vod.haohuanjiao.com/huanjiao/specialistVideo/863398/008b58c4-6f35-4e2f-ad55-aab737810eb4.tmp?a=0&auth_key=1789067908-592702f052a14401aa0f2f212f445122-0-be5261314abbf7c703c7e1fc822cebd9&br=762&bt=762&cd=0%7C0%7C0&ch=0&cr=0&cs=0&dr=0&ds=3&eid=v0247cg10004d1553u2ljht831lkvp9g&er=0&l=202608111715214E3B9F310569CF3C5E98&lr=&mime_type=video_mp4&net=0&pl=0&qs=13&rc=anNuNDtrb3g4NDczNGY3M0ApPHlvNndtNTY4ZzMzajo1eWc2c2kwcWcvMDJhLS1kNC9zc2RtaC41ZWlyMi4xLS5gMS06Yw%3D%3D&vl=&vr=",true,{"code":9,"msg":59,"message":6,"data":6,"success":60},{"code":9,"msg":10,"message":6,"data":63,"success":60},{"pageNo":30,"pageSize":64,"result":65,"totalSize":17},10,[],{"code":9,"msg":10,"message":6,"data":67,"success":60},{"authors":68,"appraiseDimensionScoresVos":69},[],[]]